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Dr. Leppik raised some important issues regard-
ing the mechanism of action of zonisamide. There
is a great deal of interest in the impact of zon-
isamide on the T-type calcium channel. However,
the relevance of that mechanism to the clinical
experience is not known. The drug’s impact on the
sodium channel is one that is not unique to this
antiepilepsy drug (AED).
There is some unpublished scientiﬁc evidence
about the impact of zonisamide on glutamate, a
story that likely will continue to develop. Dr. Leppik
cited the work of Dr. Miura and other investigators
in Japan who have identiﬁed a link between the
neuroprotective impact of zonisamide and some of
the brain’s methods of handling glutamate. There
are six or seven different strategies that the brain
uses to keep glutamate under control, and zon-
isamide may have an impact on one or two of those
mechanisms. The Japanese investigators, and per-
haps investigators around the world, will be looking
more closely at this issue of neuroprotection. Dr.
Leppik provided an introduction to this concept
and we hope to see more information in the future.
As far as the pharmacokinetics of this drug,
the half-life of zonisamide when combined with
other drugs deserves attention. With zonisamide
monotherapy or when zonisamide is given to a
naive patient, the drug’s half-life approaches 70 h.
While the effects of other AEDs were discussed,
experience with non-AED medications remains
a question.
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For example, in the United States, assessing the
potential for contraceptive failure due to an inter-
action between zonisamide and oral contraceptives
is of particular interest. Since oral contraceptives
have not until recently been available in Japan,
contraceptive failure has not been an issue or an
observation in Japan. However, it is certainly a
very practical question in the United States. Con-
traceptive failure in patients taking AEDs is a dis-
appointing experience, so it is very important to
know of any potential interactions in advance.
The half-life of zonisamide is essentially cut
in half by the concomitant use of liver enzyme-
inducing AEDs, particularly carbamazepine. The
half-life of zonisamide drops to between 27 and
38 h when used with carbamazepine, phenytoin, or
phenobarbital.
While zonisamide is not a cytochrome P450 3A4
inducer, it may possibly induce other liver enzymes.
The interaction with valproate was a curious obser-
vation, and the signiﬁcance of this effect has not
been determined. Valproate has a greater impact
on the beta oxidation series than on the omega
oxidation series, but it is not known whether that
particular mechanism is operant in this case.
Red blood cell binding of zonisamide was dis-
cussed, and this binding can be very important in
terms of plasma assay, as Dr. Leppik warns. Zon-
isamide is not the only drug that tends to sequester
in red blood cells; there are others and hemolysis
can be a problem.
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